Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i21.106939

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-7)

Tables (1-6)

Sum=0

Jun 7, 2025 (publication date) through Jun 6, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939

Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Zhao Gao, Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Xiao-Yun Wang, Shi-Kai Wu, Xuan Jin

Zhao Gao, Xiao-Yun Wang, Shi-Kai Wu, Xuan Jin, Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China

Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Department of Pharmacy, Jilin Cancer Hospital, Changchun 130012, Jilin Province, China

Co-corresponding authors: Shi-Kai Wu and Xuan Jin.

Author contributions: Gao Z collected and analyzed the data; Gao Z and Wang XY wrote the manuscript; Shen ZG, Liu JH, and Jin X analyzed the data; Jin X and Wu SK conceived of the review and edited the manuscript, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors read and approved the final manuscript.

Supported by the National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital), No. 2022CR65.

Institutional review board statement: This study was approved by the Medical Ethics Committee of Peking University First Hospital (approval No.2023-505-003) and Jilin Cancer Hospital (approval No. 202501-003-01).

Informed consent statement: The informed consent was waived by the Institutional Review Board.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shi-Kai Wu, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. skywu4923@sina.cn

Received: March 11, 2025
Revised: April 23, 2025
Accepted: May 23, 2025
Published online: June 7, 2025
Processing time: 87 Days and 7.3 Hours

Core Tip

Core Tip: This manuscript addresses to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line regimen for microsatellite stable metastatic colorectal cancer. As there is currently no clinical data on the second-line treatment of advanced colorectal cancer with the combination of immunotherapy, anti-angiogenic drugs, and anti-programmed death 1 immunotherapy, we conducted a multicenter retrospective cohort clinical study to explore the safety and efficacy of this triplet therapy in second-line treatment of advanced colorectal cancer patients.